Gina Hernandez, PA
Physician Assistant · Ardmore, OKNPI 1760403943
Payments from drug & device makers
Across 253 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$582
- Novo Nordisk$462
- Lilly USA, LLC$453
- AstraZeneca$299
- Amgen$272
- Takeda Pharmaceuticals U.S.A., Inc.$266
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,849100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $582 |
| Novo Nordisk | 26 | $462 |
| Lilly USA, LLC | 34 | $453 |
| AstraZeneca | 20 | $299 |
| Amgen | 19 | $272 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $266 |
| Sanofi-aventis U.S. LLC | 15 | $237 |
| Bayer | 16 | $225 |
| GSK | 18 | $196 |
| Boehringer Ingelheim | 7 | $113 |
| Merck | 8 | $112 |
| Astellas Pharma US Inc | 5 | $108 |
| Corium, LLC | 2 | $58 |
| Organon | 6 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Boston Scientific | 1 | $44 |
| Biogen | 3 | $43 |
| Amarin Pharma, Inc. | 3 | $40 |
| Pfizer | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Tactile Systems Technology Inc | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Novartis | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$3,849 in reported general payments places this provider in the 85th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $81,766 |
| Humira PenAdalimumab | 12 | $81,739 |
| MounjaroTirzepatide | 53 | $65,211 |
| OzempicSemaglutide | 54 | $63,444 |
| EliquisApixaban | 57 | $52,778 |
| FarxigaDapagliflozin Propanediol | 35 | $38,483 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $31,069 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $19,932 |
| Repatha SureclickEvolocumab | 32 | $18,663 |
| XareltoRivaroxaban | 18 | $18,246 |
| JanuviaSitagliptin Phosphate | 14 | $17,832 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $16,552 |
| TrulicityDulaglutide | 14 | $14,884 |
| KerendiaFinerenone | 19 | $14,486 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $13,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $453 | $80,09567 claims |
| Novo NordiskOzempic | $462 | $63,44454 claims |
| PfizerEliquis | $30 | $52,77857 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $299 | $48,35349 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $196 | $36,26052 claims |
| MerckJanuvia, Janumet | $112 | $26,93228 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $237 | $19,93220 claims |
| Johnson & JohnsonXarelto | $11 | $18,24618 claims |
| BayerKerendia | $225 | $14,48619 claims |
| Boehringer IngelheimSynjardy Xr | $113 | $13,00911 claims |
| AbbVieArmour Thyroid | $582 | $1,09115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Ardmore
- Shelby LucasArdmore$10K
- Robert HannaArdmore$8K
- Eric CampbellEdmond$246K
- Katherine DemersEl Reno$146K
- Jennifer SmithOklahoma City$134K
- Christy NiehuesMustang$28K
- Matthew PattonTulsa$24K
- Sarah HawkOklahoma City$23K
- Gavin ChristieEdmond$19K
- Michelle GreenTulsa$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.